
Small-Cap Momentum Watch: Upcoming Catalysts for November 16–20
11/15/202616 min read
From operational updates to conference participation, we’ve highlighted the small-cap events that could drive attention this week.
--
Companies Participating at the Jefferies Global Healthcare Conference London 2026
The Jefferies Global Healthcare Conference will take place November 16–19, 2026, at The Waldorf Hilton in London, United Kingdom. Hosted by Jefferies, the four-day event brings together more than 800 public and private companies across biotechnology, pharmaceuticals, medical technology, healthcare services, and other healthcare sectors, along with institutional investors, industry executives, and financial professionals. The conference will feature company presentations, fireside chats, one-on-one investor meetings, and discussions focused on clinical development, regulatory milestones, commercialization, strategic partnerships, and emerging investment opportunities across the global healthcare industry.
RLMD, TLSA, OKYO, ACRS, CTXR, IBIO, CTSO, AQST, NBP, CGTX, PRME, ANTX, XFOR, FHTX, FATE, CLLS, EQ, NUVB, ARDX, ALXO, MNKD, VNDA, VRCA, CCCC, AUTL, ABEO, CVRX, RZLT, BDTX, WVE, LXRX, MGX, RXRX, INO, ACIU, KYTX, CTMX, CABA, SPRO, IPSC, FOCL, HYPR, CRBP, ADCT
Companies Participating at the UBS Global Biopharma Conference 2026
The inaugural UBS Global Biopharma Conference will take place November 16–17, 2026, at the Rosewood Hotel in London, United Kingdom. Hosted by UBS, the two-day event brings together biotechnology and pharmaceutical companies, institutional investors, financial analysts, and healthcare industry executives for corporate presentations, fireside chats, one-on-one investor meetings, and discussions focused on drug development, clinical trial progress, regulatory milestones, emerging therapeutic technologies, commercialization strategies, and strategic partnerships across the global biopharmaceutical industry.
MOLN, CRDF, ENGN, SABS, EYPT
Companies Participating at the 17th Annual Craig-Hallum Alpha Select Conference 2026
The 17th Annual Craig-Hallum Alpha Select Conference will take place November 17, 2026, at the Sheraton New York Times Square Hotel in New York City. Hosted by Craig-Hallum Capital Group, the one-day event brings together emerging-growth and small-cap public companies, institutional investors, industry executives, and financial professionals across technology, healthcare, industrials, consumer products, and other sectors. The conference primarily features one-on-one investor meetings, providing participating companies opportunities to discuss business developments, commercialization strategies, operational progress, strategic initiatives, and future growth opportunities.
BODI, AIOT, CRNT, CREX, ELWT, OABI, MDXG, KRMD, MYO, EVLV, HIT
Companies Participating at the 15th Annual ROTH Technology Conference 2026
The 15th Annual ROTH Technology Conference will take place November 17–18, 2026, at the Hard Rock Hotel in New York City. Hosted by ROTH Capital Partners, the two-day event brings together approximately 120 public and private technology companies, institutional investors, industry analysts, and corporate executives for one-on-one and small-group investor meetings, panel discussions, and fireside chats. The conference will focus on artificial intelligence, data center infrastructure, cybersecurity, robotics, semiconductors, aerospace and defense technologies, enterprise software, quantum computing, digital assets, and emerging technology investment opportunities.
XTND, BGIN, ELVA, RCT, TMS, MRLN, PDYN, NXDR, ODYS
Companies Participating at RE+ 2026
RE+ 2026 will take place November 16–19, 2026, at the Las Vegas Convention Center in Las Vegas, Nevada. Co-hosted by the Solar Energy Industries Association and the Smart Electric Power Alliance, the four-day event brings together companies, utilities, developers, manufacturers, investors, and industry professionals across solar energy, battery storage, electric vehicle infrastructure, hydrogen, wind power, and grid technologies. Educational programming will run November 16–18, with exhibition activities November 17–19, featuring product showcases, technology demonstrations, networking, and discussions focused on energy infrastructure, grid reliability, domestic manufacturing, and renewable energy commercialization.
XOS, BESS, TOYO, NEOV
Companies Participating at the RBC Capital Markets Global Technology, Internet, Media & Telecommunications Conference 2026
The RBC Capital Markets Global Technology, Internet, Media & Telecommunications Conference will take place November 17–18, 2026, in New York City. Hosted by RBC Capital Markets, the two-day event brings together technology, telecommunications, internet, media, software, and digital services companies with institutional investors, industry executives, and research analysts for keynote presentations, fireside chats, panel discussions, and investor meetings. Discussions will focus on artificial intelligence, cloud and data center infrastructure, cybersecurity, digital transformation, advertising technology, communications networks, and emerging opportunities across the technology sector.
COUR, CCOI, TBLA, MNTN, CLVT
Companies Participating at the Stephens Annual Investment Conference 2026
The 28th Annual Stephens Investment Conference, also known as NASH2026, will take place November 17–19, 2026, at the Grand Hyatt Nashville in Nashville, Tennessee. Hosted by Stephens, the three-day event brings together publicly traded companies, institutional investors, corporate executives, and financial analysts across healthcare, technology, consumer products, industrials, energy, transportation, and other sectors. The conference will feature fireside chats, management presentations, one-on-one investor meetings, and discussions focused on operating performance, strategic initiatives, market trends, commercialization opportunities, and long-term growth strategies.
PACB, ZVIA, PAL, MXCT
Companies with Material Events This Week
CNSY - Will host an investor conference call on November 16, 2026, at 8:30 a.m. ET to review clinical findings from its ReSPECT-LM program evaluating rhenium-186 radiotherapy for leptomeningeal metastases. Management will also provide an update on commercialization of its CNSide diagnostic platform.
BMEA - Will present Phase 1 clinical findings for BMF-650 at ObesityWeek 2026 on November 16 from 2:30-3:30 p.m. ET. Management will also participate in a Jefferies Global Healthcare Conference fireside chat on November 19 at 8:30 a.m. ET to discuss its metabolic disease development programs.
TMCR - Will host a corporate update webinar on November 16, 2026, at 11:00 a.m. ET. Management will review its critical minerals royalty portfolio, including its 2% Mesabi mineral royalty interest, and discuss investment opportunities and regulatory developments affecting seabed mining.
OVID - Will participate in the UBS European Healthcare Conference in London on November 16 at 2:40 p.m. GMT. Management will discuss its central nervous system development pipeline, including OV329 for treatment-resistant seizures and its KCC2 activator programs.
PCSA - Executive Chair Dr. Sheila Gujrathi will participate in a fireside chat at the UBS Global Biopharma Conference in London on November 16 at 4:00 p.m. GMT. The discussion will focus on the company's clinical development strategy and advancement of VT-7208, its lead oral BTK inhibitor program acquired through Vidya Therapeutics.
LSTA - Will participate in the LifeSci Growth and Innovation Summit on November 16 and present at the Jefferies Global Healthcare Conference in London on November 17 at 8:00 a.m. GMT. Management will discuss subsidiary Marea Therapeutics' Phase 2b MAR001 program for severe hypertriglyceridemia and MAR002 for acromegaly.
TROX - November 16, 2026, is the record date for Tronox's quarterly cash dividend of $0.05 per common share, scheduled for payment January 15, 2027.
RBNE - November 16, 2026, is the record date for Robin Energy's special cash dividend of $0.10 per common share, with payment expected November 20. Nasdaq due-bill procedures will apply through November 20, with shares expected to trade ex-dividend beginning November 23, meaning entitlement depends on the due-bill rules rather than the ordinary record-date convention.
PMN - Will present previously disclosed interim safety and biomarker findings from its Phase 1b PRECISE-AD trial of PMN310 at the Clinical Trials on Alzheimer's Disease Conference (CTAD), November 16-19, in Boston. The investigational antibody targets toxic amyloid-beta oligomers, with 12-month topline study results expected in Q1 2027.
CRVO - Will present 24-week biomarker data from its ongoing Phase 2a neflamapimod trial in nonfluent variant primary progressive aphasia at CTAD 2026, November 16-19, in Boston. The presentation will provide a longer-duration assessment of neuronal injury biomarkers following preliminary 12-week findings reported in October.
AVXL - Will present a scientific poster at CTAD 2026, November 16-19, in Boston, Massachusetts. The company will also participate as a Silver Sponsor at the conference focused on Alzheimer's disease research, clinical development, and emerging treatment approaches.
CODX - Will participate in the New Tools Summit on November 16 in Rio de Janeiro, Brazil, followed by the Union World Conference on Lung Health, November 17-20. The company will engage international tuberculosis programs and diagnostic partners regarding its CoSara PCR Pro platform and tuberculosis testing products under development for commercial introduction in India.
LINK - Will exhibit its medical-grade sensor technologies at MEDICA 2026, November 16-19, in Dusseldorf, Germany. The company will showcase force-sensing, wearable electronics, and patient-monitoring applications while pursuing medical device partnerships and commercial integration opportunities.
RR - Will introduce its camera-integrated Intelligent Cleaning System at ISSA Show North America, November 17-19, in Las Vegas. The system combines CCTV monitoring with DUST-E autonomous cleaning robots to identify cleaning needs and initiate tasks. Executive Sales Director Christian Barnes will also present on integrated robotic floor-care programs November 16 at 11:00 a.m. PT.
VIVS - Will present two scientific posters at the American College of Toxicology's Annual Meeting, November 15-18, in San Antonio, Texas. The presentations will highlight drug-safety testing using its NAMkind human 3D liver and intestinal tissue platforms, including applications in liver injury and gastrointestinal toxicity.
GANX - Will present preclinical findings for GT-04686, its investigational GCase allosteric modulator, at Neuroscience 2026 on November 17 from 8:00-9:00 a.m. ET. The poster will highlight reductions in neuropathology and improvements in motor and nonmotor function in a GBA1-associated Parkinson's disease model.
DDD - Will participate in Formnext 2026 in Frankfurt, Germany, with a November 17 presentation at 3:45 p.m. local time featuring co-founder Chuck Hull and Senior Vice President Patrick Dunne. The company will also showcase additive manufacturing technologies during its 40th-anniversary event on November 18.
VBIO - Will participate in Baird's National Security Conference on November 17 in Washington, D.C., highlighting Entolimod as a potential radiation countermeasure. The company is advancing a government-funded animal efficacy study for gastrointestinal acute radiation syndrome, with topline results expected in early December 2026.
CANF - Will participate in BIO-Europe's digital partnering sessions November 17-18, following the November 9-11 in-person conference. Business development discussions will focus on licensing and co-development opportunities involving its pancreatic cancer program and ongoing Phase 3 development activities.
PRSO - Will demonstrate its DUNE 60 GHz millimeter-wave wireless networking technology at Africa Tech Festival, November 17-19, in Cape Town, South Africa. The company will engage telecommunications operators and distribution partners regarding fixed wireless broadband deployments and commercial expansion opportunities.
NUR - CEO Francis Letourneau will participate in Africa Tech Festival, November 17-19, in Cape Town, meeting telecommunications operators, government representatives, and infrastructure partners. Discussions will focus on financing and expanding the company's African tower network toward its targeted 1,650 operating sites.
HOVR - Will deliver a keynote presentation at The eVTOL Show on November 17, 2026, in San Jose, California. Management will discuss development of its hybrid-electric vertical takeoff and landing aircraft, including its combination of vertical flight capabilities and conventional wing-borne cruise performance.
SABR - Will host an Investor Day in New York City on November 17, 2026, beginning at 8:30 a.m. ET. Management will discuss strategic priorities, its multiyear business outlook, technology modernization, and artificial intelligence initiatives across its travel distribution platforms.
XTIA - Subsidiary Drone Nerds will host ElevateUAV 2026, November 17-18, at Gulfstream Park in Florida. The event will feature live drone demonstrations, commercial unmanned aircraft technologies, and discussions covering public safety, enterprise inspection, agriculture, construction, and potential industry partnerships.
QNC - Will participate as a Bronze Sponsor of the World Quantum Cannes Festival, November 17-18, in Cannes, France. The company will showcase its quantum random number generation technology and post-quantum cybersecurity solutions while exploring European commercialization and strategic partnerships.
GNPX - Will participate in the Future of Cell and Gene Therapy Symposium, November 17-18, discussing manufacturing and delivery optimization for its gene therapy programs. The company will also have oncology research presented at the EORTC-NCI-AACR Symposium on November 18, examining TROP2 as a potential predictive biomarker for its REQORSA lung cancer therapy.
HUMA - Will present five studies involving its Acellular Tissue Engineered Vessel technology at VEITHsymposium, November 17-21, in New York City. Four November 18 presentations will cover vascular reconstruction, interim Phase 3 dialysis-access findings, safety, durability, and long-term vessel remodeling. A November 19 presentation at 11:50 a.m. ET will examine Symvess clinical findings and potential military and civilian vascular trauma applications. A supplemental BLA submission for dialysis access remains planned during November.
WTI - Chairman and CEO Tracy Krohn will host a live investor presentation on November 18, 2026, at 11:00 a.m. ET. The discussion will focus on the company's offshore oil and natural gas operations, development opportunities, and corporate strategy, followed by investor questions.
UPLD - Management will participate in Needham's Virtual Tech Week One-on-One Event, November 18-19, conducting institutional investor meetings focused on its enterprise software portfolio, operating strategy, and growth initiatives.
PHIO - Will participate in Renmark Financial Communications' Virtual Non-Deal Roadshow on November 18 at 2:00 p.m. ET. CEO Robert Bitterman will discuss the company's INTASYL gene-silencing platform and PH-762 clinical development for cutaneous carcinomas, followed by a live investor Q&A.
ATHE - CEO Dr. David Stamler will present virtually at the Bell Potter Healthcare Conference on November 18 at 8:00 p.m. ET, corresponding to November 19 at noon in Australia. The presentation will focus on ATH434 for multiple system atrophy, previously reported Phase 2 findings, and preparations for a pivotal Phase 3 trial.
IMRX - Will present preclinical findings supporting atebimetinib in combination with chemotherapy for anaplastic thyroid cancer at the EORTC-NCI-AACR Symposium on November 18. The company is targeting an IND submission for a potentially registrational Phase 2 study by year-end 2026, with initial patient dosing planned around mid-2027.
IPHA - Will host an investor and scientific event on November 18 at 11:00 a.m. ET to review Phase 1 dose-escalation data for IPH4502, its Nectin-4-targeted antibody-drug conjugate. Management and an oncology expert will discuss safety, pharmacokinetics, preliminary antitumor activity, and future development opportunities in urothelial cancer.
CGEN - Will present its UnigenX AI-powered drug discovery platform at PEGS Europe in Lisbon on November 18 at 6:30 p.m. GMT. The presentation will highlight identification of tumor-associated antigens and new immunotherapy targets for T-cell engagers and multispecific antibodies.
EVAX - Will present initial research from the expansion of its AI-Immunology platform into autoimmune diseases at PEGS Europe on November 18. The presentation will cover early-stage development of a tolerogenic vaccine and an autoantibody-binding therapeutic approach.
ALZN - Will present Phase 1/2a neuroimaging findings for AL001 at Neuroscience 2026 on November 18 during the 8:00 a.m.-noon ET poster session. The study will examine changes in brain network connectivity using 7-tesla functional MRI following treatment with the company's investigational lithium formulation.
PYXS - Will present Phase 1 clinical findings for MICVO during a late-breaking oral presentation at the EORTC-NCI-AACR Symposium in Barcelona on November 19, during the 10:00-11:30 a.m. CET session. The presentation will highlight monotherapy safety, tolerability, and preliminary antitumor activity in patients with advanced solid tumors.
NUWE - Will convene a pediatric medical and nursing advisory board on November 18-19 to advance development of Vivian, its next-generation continuous renal replacement therapy system for children weighing as little as 2.5 kilograms. Specialists will review device functionality, clinical workflows, and development priorities ahead of future regulatory milestones.
BRLT - CFO Jeff Kuo will present at the Southwest IDEAS Investor Conference on November 18 at 3:20 p.m. CT in Irving, Texas. Management will discuss the company's jewelry retail business, operating strategy, customer acquisition, and growth opportunities.
SND - November 18, 2026, is the record date for Smart Sand's special cash dividend of $0.05 per common share, representing approximately $2.2 million in distributions. Payment is scheduled for November 30.
IDAI - CEO Gareth Genner will present at the OTC Markets Small Cap Growth Virtual Investor Conference on November 18 from 11:00-11:30 a.m. ET, followed by an investor Q&A at 1:00 p.m. ET. The presentation will focus on AI-powered identity verification, fraud prevention, commercial progress, and strategic priorities for 2027.
NKLR - Will participate in the Clear Street Disruptive Technology Conference, November 18-20, in New York City. Management will conduct investor meetings focused on its SOLO micro-modular nuclear reactor platform, commercialization strategy, and potential industrial and distributed power applications.
LAES - Will host its Quantum Days event on November 19 in Cannes, France, following the World Quantum Cannes Festival on November 17-18. The company will highlight developments in post-quantum cybersecurity, quantum computing, and its QS7001 secure semiconductor and QVault TPM technologies, including progress toward Common Criteria EAL5+ certification.
NAGE - CEO Rob Fried and CFO Ozan Pamir will present at the Southwest IDEAS Investor Conference on November 19 from 4:00-4:35 p.m. CT in Irving, Texas. Management will discuss the company's Niagen product portfolio, NAD+ research, commercial activities, and growth strategy.
FBLG - Will host a RedChip investor webinar on November 19 at 4:15 p.m. ET. Management will provide updates on CYWC628, its Phase 1/2 fibroblast-based therapy for diabetic foot ulcers, with clinical data expected during 2026. Additional discussion may include its psoriasis, multiple sclerosis, and degenerative disc disease programs.
NIKI - Subsidiary DiamiR Biosciences will present research at CTAD 2026 on November 19 in Boston. The poster will highlight analytical validation of APOE genetic testing using fingertip-collected dried blood spots, supporting development of more accessible Alzheimer's-related genetic risk assessment.
TWI - Management will participate in the Southwest IDEAS Investor Conference on November 19 in the Dallas area, conducting institutional investor meetings focused on its tire and wheel operations, market conditions, and business strategy.
IMMP - Will present additional analyses from its Phase 2 EFTISARC-NEO trial at the Connective Tissue Oncology Society Annual Meeting on November 19 in Seoul, South Korea. The trial evaluates eftilagimod alfa with pembrolizumab and radiotherapy in resectable soft-tissue sarcoma. Previously reported 12-month outcomes included 81.1% disease-free survival, 94.1% local recurrence-free survival, and 86.2% distant metastasis-free survival among 38 evaluable patients.
RGP - November 19, 2026, is the record date for Resources Connection's quarterly cash dividend of $0.07 per common share, payable December 17, 2026.
SEGG - Plans to relaunch Lottery.com worldwide on November 20, 2026, introducing a redesigned platform focused on lottery results, jackpot information, free games, advertising, affiliate referrals, and licensing. Initial markets include the United States and Mexico, with additional functionality and international expansion planned in phases.
FJET - Will host a rescheduled investor briefing on November 20 at 4:00 p.m. ET. CEO Tim Franta will discuss the company's STARLAUNCH air-launch system, Wind Tunnel in the Sky program, and aerospace development initiatives ahead of a planned December 2026 captive-carry test flight.
PMVP - Will present updated clinical data from all cohorts of its pivotal Phase 2 PYNNACLE trial of rezatapopt at the EORTC-NCI-AACR Symposium on November 20 at 3:00 p.m. CET. The late-breaking oral presentation will highlight efficacy, safety, and molecular activity in advanced solid tumors harboring TP53 Y220C mutations, supporting the company's planned ovarian cancer regulatory submission in 2027.
PPBT - Will deliver an oral presentation on IM1240, its lead trispecific antibody from the CAPTN-3 platform, at the EORTC-NCI-AACR Symposium on November 20 at 3:00 p.m. CET. The presentation will cover preclinical antitumor activity, NKG2A engagement, pharmacokinetics, and safety findings supporting potential first-in-human development during 2027.
ACRV - Will present updated Phase 1/2 clinical findings for ACR-2316, its dual WEE1/PKMYT1 inhibitor, at the EORTC-NCI-AACR Symposium on November 20 at 4:12 p.m. CET. The late-breaking oral presentation will focus on safety, clinical responses, and molecularly selected patient populations, building on previously reported complete and partial responses in advanced solid tumors.
APRE - Will present additional Phase 1 clinical findings for APR-1051, its investigational ATR inhibitor, at the EORTC-NCI-AACR Symposium on November 20 in Barcelona. The presentation will highlight emerging safety, dosing, pharmacodynamic, and antitumor activity data in advanced solid tumors, informing its planned dose-expansion strategy for the first half of 2027.
CATX - Will present updated clinical findings from Cohorts 1-3 of its [212Pb]VMT-alpha-NET radiopharmaceutical program at the EORTC-NCI-AACR Symposium on November 20. Poster 334 will highlight safety, treatment responses, and dose-escalation findings in patients with advanced SSTR2-positive neuroendocrine tumors, ahead of a targeted FDA End-of-Phase 2 meeting in Q1 2027.
QNC - Quantum eMotion's proposed acquisition of Plurilock Security will be presented for shareholder approval at a special meeting on November 18, with proxies due November 16. Plurilock shareholders would receive C$0.084 in cash plus 0.0763 QNC share per share, with closing targeted for late November, subject to shareholder, court, and regulatory approvals.
BURU - NUBURU's 70%-owned Tekne subsidiary submitted proposals to two U.S. Army defense competitions covering electronic warfare, surveillance, and counter-drone systems, with the Counter-UAS submission deadline November 17. The competitions offer combined potential prize and prototype funding of up to $13.5 million, with finalist demonstrations planned for February-March 2027. Tekne is also evaluating a NATO tender for six portable jamming systems, with bids due November 30.
AIRI - Will hold a special shareholder meeting November 18 to approve share issuance for its proposed merger with Tenax Aerospace Acquisition and increase authorized shares from 20 million to 200 million. A 1-for-5 reverse split is planned for November 20, with merger completion targeted by November 30. Existing AIRI shareholders are expected to retain approximately 4% of the combined company, although a recent dispute over debt amendments creates additional closing uncertainty.
DGNX - Extended the closing deadline for its proposed acquisition of Resulticks to November 19 after outstanding conditions remained unsatisfied. The company will also hold an extraordinary shareholder meeting November 20 to approve increasing authorized ordinary shares from 495 million to 1.295 billion and a proposed 1-for-10 share consolidation. These proposals may proceed independently of the acquisition, which remains subject to completion of its closing conditions.
HSCS - Will hold a special shareholder meeting November 19 to approve its proposed all-stock merger with Fortitude Mining Holdings, a Digital Currency Group subsidiary focused on Zcash mining. The proposals include a potential 1-for-2 to 1-for-5 reverse split and authorization for up to 35 million additional shares. The combined company is expected to trade as TUDE, with Digital Currency Group controlling approximately 94% of voting interests and closing targeted for Q4 2026.
EDVA - Endovia Health Sciences and Lupvindol BioSciences are scheduled to meet with the FDA's Center for Veterinary Medicine on November 19 to discuss CannEpil's development requirements, manufacturing standards, and regulatory pathway. CannEpil previously qualified for the FDA's Minor Use and Minor Species conditional approval pathway for treating bone-cancer-related pain in dogs, with U.S. manufacturing preparations underway toward a potential 2027 veterinary launch.
IBO - Impact Biomedical's proposed business combination with Zoar Limited remains pending following its November 13 shareholder meeting, with November 20 established as the amended outside closing date. The combined company is expected to trade on NYSE American under ZOAR, subject to confirmation of shareholder approval, exchange listing approval, and remaining closing conditions.
GRDX - GridAI Technologies expects to close its acquisition of Pronghorn Resources, a Wyoming natural-gas and energy-infrastructure platform, on or before November 22. The acquisition includes approximately 100 MMcf/day of gross gas production, nearly 2 Tcf of estimated 3P reserves, and more than 450 miles of pipelines. GridAI plans to leverage the assets for AI data-center power generation, targeting 300 MW of initial power delivery in 2027, with transaction consideration including common shares and approval-dependent convertible preferred stock.
SEED - Origin Agritech's mandatory 30-day public-notice period for three newly developed corn varieties ends November 22, following successful preliminary Chinese national review. Two-year regional trials demonstrated yield improvements of 6.0%-8.6% over control varieties, with final regulatory approval and commercial seed introduction pending completion of the approval process.
IMCC - IM Cannabis is targeting approximately November 22 to execute definitive agreements for its proposed acquisition of 51% of Space Defense Innovations, a Polish tactical drone and unmanned aircraft business operating through BlueAero Group. The company confirmed on November 13 that negotiations remain ongoing, with the proposed transaction involving equity consideration, a seller loan, and a potential EUR 2.3 million credit facility, subject to due diligence and required approvals.
--
Disclaimer: All content provided by BigTimePennys Report is for informational purposes only. The information provided should not be considered as a substitute for professional advice, analysis, or guidance. Any investment decisions made based on the information provided are solely at the user's own risk. BigTimePennys Report are not liable for any losses or damages incurred as a result of using this information. BigTimePenny is not operated by a licensed broker, a dealer, or a registered investment adviser. The Securities Litigation Reform Act of 1995 provides safe harbor protection for forward-looking statements made by companies or individuals. It should be noted that any forward-looking statements made by BigTimePennys Report, its authors, are not guarantees of future performance or results. These statements are subject to risks, uncertainties, and assumptions that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. The content provided by BigTimePennys Report does not constitute an endorsement, recommendation, or solicitation to buy, sell, or hold any securities or investment products. BigTimePennys Report, its authors, do not endorse or recommend any specific investment strategies, securities, or companies. It is crucial to conduct thorough research and seek advice from a qualified professional before making any investment decisions. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. The user assumes full responsibility for the use of the information provided by BigTimePennys Report. BigTimePennys Report, its authors, disclaim any liability for any direct, indirect, or consequential damages arising from the use or reliance on the information provided. Users should exercise their own judgment and discretion when interpreting and utilizing the information provided. Please note that the content provided by BigTimePennys Report is based on available information and sources believed to be reliable. However, market conditions and regulations may change over time, and there may be inaccuracies or errors in the information provided. It is recommended to verify the information with current and reliable sources before making any investment decisions. Investing in micro-cap companies is highly speculative and carries an extremely high degree of risk. BigTimePenny is not a fiduciary by virtue of any person's use of or access to this content. We were NOT compensated for this article.

Disclaimer: Penny stock trading involves substantial risk, so always research every alert before trading, consult with a licensed professional before trading, only invest what you can afford to lose, and always trade with caution. Readers should independently investigate and fully understand all risks before investing. Results listed are NOT typical and individual results may and most likely will vary. Bigtimepennystocks.com and its staff are NOT licensed investment advisors or broker/dealers of any kind.Alerts are not a solicitation or recommendation to buy/sell/hold securities but merely investment ideas that should NEVER serve as the basis of your trading decisions. Bigtimepennystocks.com and its newsletter are for entertainment purposes only. This website and its reports are for general information purposes as we are engaged in the business of marketing and advertising companies for monetary compensation. Any investment decision should be discussed with a financial adviser before taking place. Please invest carefully and read investment information available at the website of the SEC at http://www.sec.gov.
Subscribe to our Free Newsletter
Copyright © 2023 BigTimePennyStocks.com - All Rights Reserved.
